Research programme: age-related macular degeneration - Scotia Holdings
Alternative Names: Age-related macular degeneration research programme - Scotia HoldingsLatest Information Update: 22 Jan 2002
Price :
$50 *
At a glance
- Originator Scotia Holdings [CEASED]
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 22 Jan 2002 Discontinued-Preclinical for Age-related macular degeneration in United Kingdom (Unknown route)
- 02 May 2000 New profile
- 02 May 2000 Preclinical development for Age-related macular degeneration in United Kingdom (Unknown route)